PE09802008A1 - alpha anti-lymphotoxin antibody - Google Patents

alpha anti-lymphotoxin antibody

Info

Publication number
PE09802008A1
PE09802008A1 PE2007001374A PE0013742007A PE09802008A1 PE 09802008 A1 PE09802008 A1 PE 09802008A1 PE 2007001374 A PE2007001374 A PE 2007001374A PE 0013742007 A PE0013742007 A PE 0013742007A PE 09802008 A1 PE09802008 A1 PE 09802008A1
Authority
PE
Peru
Prior art keywords
sequence
cdr
n0
antibody
sequence identifier
Prior art date
Application number
PE2007001374A
Other languages
Spanish (es)
Inventor
Camellia W Adams
Jane L Grogan
Austin L Gurney
Krista Mccutcheon
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US82925706P priority Critical
Priority to US93899907P priority
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE09802008A1 publication Critical patent/PE09802008A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • C07K16/242Lymphotoxin [LT]
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06QDATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00Subject matter not provided for in other groups of this subclass
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

SE REFIERE A UN ANTICUERPO QUE COMPRENDE: A) UNA SECUENCIA CDR-L1 QUE COMPRENDE LOS IDENTIFICADORES DE LAS SECUENCIAS N0 1, 2, 3, 4 o 6; MEANS an antibody comprising: a) a sequence CDR-L1 IDENTIFIERS COMPRISING SEQUENCES N0 1, 2, 3, 4 or 6; B) UNA SECUENCIA CDR-L2 QUE COMPRENDE UN IDENTIFICADOR DE SECUENCIA N0 7, 8; B) A CDR-L2 SEQUENCE COMPRISING SEQUENCE IDENTIFIER N0 7, 8; C) UNA SECUENCIA CDR-L3 QUE COMPRENDE UN IDENTIFICADOR DE SECUENCIA N0 9, 11, 13, 14, 15; C) a sequence CDR-L3 COMPRISING SEQUENCE IDENTIFIER N0 9, 11, 13, 14, 15; D) UNA SECUENCIA CDR-H1 QUE COMPRENDE UN IDENTIFICADOR DE SECUENCIA N0 16, 17; D) A CDR-H1 SEQUENCE COMPRISING SEQUENCE IDENTIFIER N0 16, 17; E) UNA SECUENCIA CDR-H2 QUE COMPRENDE UN IDENTIFICADOR DE SECUENCIA N0 18, 19, 101, 110; E) a CDR-H2 SEQUENCE COMPRISING A SEQUENCE IDENTIFIER N0 18, 19, 101, 110; F) UNA SECUENCIA CDR-H3 QUE COMPRENDE UN IDENTIFICADOR DE SECUENCIAS N0 20, 21, 22. DICHO ANTICUERPO SE UNE AL TRIMERO DE LA LINFOTOXINA-ALFA (LTALFA3) Y BLOQUE LA INTERACCION DE LA LTALFA3 CON EL RECEPTOR I DEL FACTOR DE NECROSIS TUMORAL (TNFRI) Y EL RECEPTOR II DEL FACTOR DE NECROSIS TUMORAL (TNRFII), UTIL EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE F) a CDR-H3 COMPRISING SEQUENCES SEQ ID N0 20, 21, 22. Said antibody trimer lymphotoxin-alpha (LTALFA3) AND BLOCK JOINS THE INTERACTION WITH RECEIVER LTALFA3 I TUMOR NECROSIS FACTOR (TNFRI) AND RECEIVER II TUMOR NECROSIS FACTOR (TNRFII), useful in the treatment of Rheumatoid Arthritis
PE2007001374A 2006-10-12 2007-10-11 alpha anti-lymphotoxin antibody PE09802008A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US82925706P true 2006-10-12 2006-10-12
US93899907P true 2007-05-18 2007-05-18

Publications (1)

Publication Number Publication Date
PE09802008A1 true PE09802008A1 (en) 2008-09-02

Family

ID=39430415

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001374A PE09802008A1 (en) 2006-10-12 2007-10-11 alpha anti-lymphotoxin antibody

Country Status (21)

Country Link
US (4) US7923011B2 (en)
EP (1) EP2084188A2 (en)
JP (1) JP5298021B2 (en)
KR (1) KR20090078349A (en)
AR (1) AR063257A1 (en)
AU (1) AU2007324135B2 (en)
BR (1) BRPI0715580A2 (en)
CA (1) CA2665644A1 (en)
CL (1) CL2007002926A1 (en)
CO (1) CO6220841A2 (en)
CR (1) CR10705A (en)
IL (1) IL197937D0 (en)
MA (1) MA30876B1 (en)
MX (1) MX2009003774A (en)
NO (1) NO20091841L (en)
NZ (1) NZ576032A (en)
PE (1) PE09802008A1 (en)
RU (1) RU2486201C2 (en)
TW (1) TWI414531B (en)
UA (1) UA94484C2 (en)
WO (1) WO2008063776A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2340305A1 (en) * 2008-09-26 2011-07-06 Eureka Therapeutics, Inc. Cell lines and proteins with variant glycosylation pattern
AU2009298708A1 (en) * 2008-09-30 2010-04-08 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to lymphotoxin antagonists
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche highly concentrated anti-CD20 antibody of pharmaceutical formulations. Use of the formulation. treatment method.
WO2011060015A1 (en) 2009-11-11 2011-05-19 Genentech, Inc. Methods and compositions for detecting target proteins
EP2555797A4 (en) * 2010-04-07 2014-02-12 Abbvie Inc Tnf- binding proteins
CN103025354A (en) 2010-06-02 2013-04-03 大日本住友制药株式会社 Treatment drug for autoimmune diseases and allergic diseases
CN102621310B (en) * 2011-01-28 2014-07-02 上海科新生物技术股份有限公司 Colloidal gold chromatography anti-U1-RNP antibody detection test paper and preparation method thereof
KR20130036993A (en) * 2011-10-05 2013-04-15 삼성전자주식회사 Antibodies specifically binding to epitope in sema domain of c-met
WO2013114164A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
GB201314052D0 (en) 2013-08-06 2013-09-18 Apitope Int Nv Peptides
EP2935611A1 (en) * 2013-10-14 2015-10-28 SynAffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
WO2015057906A1 (en) * 2013-10-16 2015-04-23 Janssen Biotech, Inc. Cd200 receptor 1 agonists
KR101820572B1 (en) * 2015-08-12 2018-01-19 가톨릭대학교 산학협력단 Method for providing the information for chronic myeloid leukemia

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4920196A (en) 1982-07-30 1990-04-24 Genentech, Inc. Human lymphotoxin
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4959457A (en) 1984-05-31 1990-09-25 Genentech, Inc. Anti-lymphotoxin
IL75318A (en) * 1984-05-31 1994-08-26 Genentech Inc Recombinant human lymphotoxin and methods for its recombinant production
US5683688A (en) 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035D0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
EP0308936B1 (en) 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antibody heteroconjugates for the killing of HIV-infected cells
JPH023698A (en) 1988-06-20 1990-01-09 Denka Seiken Co Ltd Monoclonal antibody against human lymphotoxin, hybridoma capable of producing the same antibody, method for purifying and measuring human lymphotoxin using the same antibody and measuring reagent
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6475787B1 (en) 1989-07-28 2002-11-05 Wyeth Method for producing monoclonal antibodies
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5670149A (en) 1990-06-27 1997-09-23 Biogen, Inc. Lymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
DE69132629D1 (en) 1990-06-27 2001-07-12 Biogen Inc Surface complexation of lymphotoxin
US7030080B2 (en) 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
KR100272077B1 (en) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
DE69129154D1 (en) 1990-12-03 1998-04-30 Genentech Inc A method for enrichment of protein variants with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US20050255104A1 (en) 1993-01-29 2005-11-17 Centocor, Inc. Methods of treating psoriasis using anti-TNF receptor fusion proteins
DE69233367D1 (en) 1991-04-10 2004-07-22 Scripps Research Inst Libraries of heterodimeric receptors by phagemids
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッドGenentech,Inc. Immunoglobulin mutant
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
RU2048521C1 (en) * 1992-05-25 1995-11-20 Научно-Исследовательский Конструкторско-Технологический Институт Биологически Активных Веществ Method of preparing polypeptide showing human lymphotoxin property
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
AT199392T (en) 1992-12-04 2001-03-15 Medical Res Council Multivalent and multispecific binding proteins whose production and use
US5747023A (en) 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1997038123A1 (en) 1996-04-05 1997-10-16 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US5747373A (en) * 1996-09-24 1998-05-05 Taiwan Semiconductor Manufacturing Company Ltd. Nitride-oxide sidewall spacer for salicide formation
US7255854B1 (en) 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
DE69736244T2 (en) 1996-10-25 2007-05-31 Biogen Idec Ma Inc., Cambridge Soluble lymphotoxin-beta receptors, anti-lymphotoxin antibody, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
AU4930399A (en) * 1998-07-29 2000-02-21 Kyowa Hakko Kogyo Co. Ltd. Novel Polypeptide
TR200504220T2 (en) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Active lymphotoxin-beta receptor immunoglogulin şimeaktif lymphotoxin-beta receptor immunoglogulin yöntem.ırıl to a method for high level expression and purification of high-level expression of the chimeric protein and saflaştrik protein.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (en) * 1999-01-15 2011-08-31 Genentech, Inc. Polypeptide variants with altered effector function
DE60045240D1 (en) 1999-03-02 2010-12-30 Centocor Inc Antibodies against TNF-alpha for the treatment of steroid resistant asthma
EP1914244B1 (en) 1999-04-09 2013-05-29 Kyowa Hakko Kirin Co., Ltd. Method of modulating the activity of functional immune molecules
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
ES2637801T3 (en) 2000-04-11 2017-10-17 Genentech, Inc. multivalent antibodies and uses thereof
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US20060034830A1 (en) 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US20060034828A1 (en) 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
AU2001276842B2 (en) 2000-06-28 2007-04-26 Glycofi, Inc. Methods for producing modified glycoproteins
US20060029604A1 (en) * 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
MXPA03003144A (en) 2000-10-13 2004-12-06 Biogen Inc HUMANIZED ANTI-LT-bgr;-R ANTIBODIES.
US7833525B2 (en) 2000-12-28 2010-11-16 Bhami Shenoy Crystals of whole antibodies and fragments thereof and methods for making and using them
US20050271663A1 (en) 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1478740A2 (en) 2001-07-27 2004-11-24 Human Genome Sciences, Inc. Heteromultimeric tnf ligand family members
AU2002339845B2 (en) 2001-08-03 2009-03-26 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2003035835A2 (en) 2001-10-25 2003-05-01 Genentech, Inc. Glycoprotein compositions
AU2002359495A1 (en) 2001-11-30 2003-06-17 Centocor, Inc. Anti-tnf antibodies, compositions, methods and uses
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003215130A1 (en) * 2002-02-08 2003-09-02 Wyeth Composition and method for modulating an inflammatory response
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
JP4628679B2 (en) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Cells in which the activity of protein decreased or deleted that are involved in the transport of Gdp- fucose
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
AU2003234706A1 (en) 2002-04-15 2003-11-03 Human Genome Sciences, Inc. Antibodies that specifically bind to tl5
CN1678625A (en) 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 Humanized anti-lymphotoyin beta receptor antibodies
US6873910B2 (en) * 2002-10-22 2005-03-29 Qualcomm Incorporated Procedure for searching for position determination signals using a plurality of search modes
AU2003287431A1 (en) 2002-10-31 2004-05-25 Biogen Idec Ma Inc. Treatment of immunological renal disorders by lymphotoxin pathway inhibitors
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
CN1753692A (en) 2002-12-20 2006-03-29 比奥根艾迪克Ma公司 Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
AU2004218354B2 (en) 2003-03-05 2009-10-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
CN1871259A (en) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 Improved antibodies having altered effector function and methods for making the same
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
JPWO2005035778A1 (en) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α1,6- fucosyltransferase preparation of antibody composition functions using an RNA that suppresses the glycosyl transferase
NZ547589A (en) 2003-11-05 2009-05-31 Glycart Biotechnology Ag CD20 antibodies with increased Fc receptor binding affinity and effector function
KR100772800B1 (en) 2003-11-17 2007-11-01 주식회사유한양행 A variable region of the monoclonal antibody against a human tumor necrosis factor ? and a gene encoding the same
JPWO2005053742A1 (en) 2003-12-04 2007-06-28 協和醗酵工業株式会社 Pharmaceutical comprising the antibody compositions
WO2005067477A2 (en) * 2003-12-08 2005-07-28 Centocor, Inc. Anti-human lymphotoxin alpha antibodies, compositions, methods and uses
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
WO2006014685A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a man3glcnac2 glycoform
AU2005269712A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAcMan5GlcNAc2 glycoform
WO2006014679A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
EP1771477A2 (en) 2004-07-21 2007-04-11 Glycofi, Inc. Immunoglobulins comprising predominantly a gal2glcnac2man3glcnac2 glycoform
JP2008507535A (en) 2004-07-21 2008-03-13 グライコフィ, インコーポレイテッド Mainly immunoglobulins, including man5glcnac2 glycoform
KR20070057839A (en) 2004-08-19 2007-06-07 제넨테크, 인크. Polypeptide variants with altered effector function
JP2006228261A (en) 2005-02-15 2006-08-31 Micron Technology Inc Negative voltage driving of digit line insulation gate
EP1888649A2 (en) 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors

Also Published As

Publication number Publication date
AU2007324135A1 (en) 2008-05-29
NO20091841L (en) 2009-07-13
RU2486201C2 (en) 2013-06-27
BRPI0715580A2 (en) 2014-06-10
CA2665644A1 (en) 2008-05-29
RU2009117680A (en) 2010-11-20
CL2007002926A1 (en) 2008-05-16
CO6220841A2 (en) 2010-11-19
UA94484C2 (en) 2011-05-10
AR063257A1 (en) 2009-01-14
AU2007324135B2 (en) 2013-06-27
US8642740B2 (en) 2014-02-04
US20090285830A1 (en) 2009-11-19
US20130011412A1 (en) 2013-01-10
US7923011B2 (en) 2011-04-12
NZ576032A (en) 2012-03-30
MA30876B1 (en) 2009-11-02
CR10705A (en) 2009-05-07
TW200825101A (en) 2008-06-16
MX2009003774A (en) 2009-04-22
TWI414531B (en) 2013-11-11
JP2010506568A (en) 2010-03-04
WO2008063776A2 (en) 2008-05-29
JP5298021B2 (en) 2013-09-25
IL197937D0 (en) 2011-08-01
WO2008063776A3 (en) 2009-03-05
US20110150865A1 (en) 2011-06-23
KR20090078349A (en) 2009-07-17
US8216807B2 (en) 2012-07-10
US8541552B2 (en) 2013-09-24
US20110208673A1 (en) 2011-08-25
EP2084188A2 (en) 2009-08-05

Similar Documents

Publication Publication Date Title
CN104004088B (en) Bispecific antibody fusions
CN105026428B (en) PD-l antibody, antigen binding fragment thereof, and pharmaceutical use
EP2514764B1 (en) Antibody molecules which bind IL-17A and IL-17F
TWI334439B (en) Anti-tnf antibodies, compositions, methods and uses
PE03172007A1 (en) Sclerostin binding agents or fragments sclerostin
NZ576040A (en) High affinity human antibodies to human il-4 receptor
CY1116167T1 (en) Farmakeftikes COMPOSITIONS katefthynomenes in RECEPTORS erb-b1
ES2523740T3 (en) Monoclonal antibodies to the fibroblast growth factor 2 receptor
RU2010126539A (en) Antibodies against vascular endothelial growth factor (vegf)
MX2007005351A (en) Anti-properdin antibodies, and methods for making and using same.
JP2009540855A (en) Antibody molecules bind to human il-17
MY162171A (en) Humanized antibodies that recognize beta amyloid peptide
EP1394253B1 (en) Anti-human ovarian cancer -anti-cd3 bispecific antibody
UY29573A1 (en) Anti-CD20 antibodies and their uses
PE00422018A1 (en) anti-OX40 antibodies and methods of use thereof
AR046639A1 (en) therapeutic combinations of anti- IGFR1
NZ579158A (en) Engineered anti-il-23p19 antibodies
RU2008134135A (en) Compounds rage protein antagonists and methods for their use
RU2014133363A (en) Cd37-binding immune therapeutic and its combination with bifunctional chemotherapeutic
RS51829B (en) Human antibodies specific for interleukin 15 (il-15)
RU2010107175A (en) human antibodies to human cd20 and their method of use
NZ586053A (en) Anti-vegf antibody compositions and methods
CY1112909T1 (en) Antibodies directed against the angiopoietin (angiopoietin) -2 AND USES these
RU2012119788A (en) Binding il-1 proteins
AR058322A1 (en) Specific binding proteins of insulin-like growth factors and uses thereof

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed